Sun Pharmaceutical Aktie
| 1 764,75INR | -42,85INR | -2,37% |
WKN DE: A0YGWC / ISIN: INE044A01036
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 42,33 |
| Life Insurance Corporation of India (Investment Portfolio) | 3,01 |
| Life Insurance Corporation of India | 2,92 |
| Government Pension Fund - Global (The) | 1,08 |
| Norges Bank Investment Management | 1,04 |
| Government of Singapore | 1,02 |
| SBI Nifty 50 ETF | 0,83 |
| GQG Partners Emerging Markets Equity Fund | 0,82 |
| Vanguard Total International Stock Index Fund | 0,63 |
| SBI S&P BSE SENSEX ETF | 0,60 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 36 000 | 37 000 | 38 000 | 24 767 | 25 894 |
| Umsatz pro Mitarbeiter in Mio. EUR | 9,12 | 9,05 | 10,17 | 17,72 | 18,48 |
Bilanz (in Mio. INR) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 316 542 | 304 421 | 350 150 | 398 619 | 434 331 |
| Summe Anlagevermögen | 365 983 | 383 804 | 363 665 | 431 268 | 440 038 |
| Summe Aktiva | 682 525 | 688 225 | 713 815 | 829 887 | 874 369 |
Bilanz (in Mio. INR) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 83 149 | 38 686 | 12 903 | 68 859 | 32 737 |
| Summe Fremdkapital | 191 278 | 193 427 | 203 154 | 236 732 | 203 309 |
| Summe Eigenkapital | 491 247 | 494 798 | 510 661 | 593 155 | 671 060 |
| Summe Passiva | 682 525 | 688 225 | 713 815 | 829 887 | 874 369 |
Adresse
| CTS No. 201 B/1, Sun House, 400063 Mumbai | |
| Telefon | +91 (22) 43244324 |
| Fax | +91 (22) 43244343 |
| Internet | http://www.sunpharma.com |
Management
|
Aalok Dilip Shanghvi
Executive Director & Head-Business Development |
|
Abhay Gandhi
Chief Executive Officer-North America |
|
Abhishek Sharma
Head-Investor Relations |
|
Anoop Deshpande
Secretary & Compliance Officer |
|
Ashok I. Bhuta
Senior GM-Secretarial |
|
Azadar Husain Khan
SVP-Corporate Relation & CSR |
|
C. S. Muralidharan
Chief Financial Officer |
|
Dilip Shantilal Shanghvi
Chairman & Managing Director |
|
Gautam Bhailal Doshi
Independent Non-Executive Director |
|
Kirti Wardhaman Ganorkar
Head-India Business |
|
Marek Honczarenko
Head-Clinical DEvelopment |
|
Meeta Chatterjee
Chief Strategy Officer |
|
Pawan Kumar Goenka
Lead Independent Director |
|
Rama Bijapurkar
Independent Non-Executive Director |
|
Reem Malki
Chief Quality Officer |
|
Rolf K. Hoffmann
Independent Director |
|
S. Damodharan
Chief Executive Officer-API Business |
|
Sanjay Khatau Asher
Independent Director |
|
Sinha Dheeraj
Chief Information Officer & Executive VP |
|
Sudhir Vrundavandas Valia
Non-Independent Non-Executive Director |
|
Suresh Kumar Rai
Chief Human Resource Officer & Senior VP |
|
Vidhi Dilip Shanghvi
VP & Head-Consumer Healthcare Nutrition |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
